Recursion, FDA Align on Familial Adenomatous Polyposis Phase 3 Trial Design; Shares Up Pre-Bell

MT Newswires Live11-18 18:41

Recursion Pharmaceuticals (RXRX) has aligned with the US Food and Drug Administration on the design of its phase 3 trial of REC-4881 to treat familial adenomatous polyposis, a genetic condition causing polyps in the colon, the company said Wednesday.

The study is expected to enroll about 200 patients aged at least 18 who have had a colectomy or proctocolectomy. It will evaluate REC-4881 at a dose of 4 milligrams, with the dosing schedule that will be decided based on data emerging from an ongoing trial, Recursion said.

The trial is on track to start in H2 2027, the company said.

Recursion shares were up 4.8% in premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment